Un estudio de amivantamab y FOLFIRI versus cetuximab/bevacizumab y FOLFIRI en participantes con cáncer colorrectal de tipo salvaje KRAS/NRAS y BRAF que han recibido quimioterapia previamente (OrigAMI-3)
Un estudio de fase 3, aleatorizado y abierto, de amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI en participantes con cáncer colorrectal metastásico, recurrente o irresecable de tipo salvaje KRAS/NRAS y BRAF que han recibido quimioterapia previa
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Acceso ampliado
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Study Contact
- Número de teléfono: 844-434-4210
- Correo electrónico: Participate-In-This-Study1@its.jnj.com
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 13353
- Reclutamiento
- Charite Universitatsmedizin Berlin Campus Virchow Klinikum
-
Frankfurt am Main, Alemania, 60488
- Reclutamiento
- Krankenhaus NorthWest
-
Heidelberg, Alemania, 69120
- Reclutamiento
- National Center for Tumor Diseases NCT
-
Mainz, Alemania, 55131
- Reclutamiento
- Universitatsmedizin der Johannes Gutenberg Universitat Mainz
-
Munich, Alemania, 81377
- Reclutamiento
- Klinikum der Universitaet Muenchen
-
-
-
-
-
Concord, Australia, 2139
- Terminado
- Concord Hospital
-
Heidelberg, Australia, 3084
- Reclutamiento
- Warringal Private Hospital
-
South Woodville, Australia, 5011
- Reclutamiento
- Queen Elizabeth Hospital
-
St Albans, Australia, 3021
- Reclutamiento
- Western Health Sunshine Hospital
-
-
-
-
-
Barretos, Brasil, 14780 070
- Reclutamiento
- Fundacao Pio XII
-
Caxias do Sul, Brasil, 95070 560
- Reclutamiento
- Fundacao Universidade de Caxias do Sul
-
Jaú, Brasil, 17210 080
- Reclutamiento
- Fundacao Doutor Amaral Carvalho
-
Porto Alegre, Brasil, 91350 200
- Reclutamiento
- Hospital Nossa Senhora da Conceicao S A
-
Salvador, Brasil, 40050 410
- Reclutamiento
- Hospital Santa Izabel Santa Casa de Misericordia da Bahia
-
São José do Rio Preto, Brasil, 15090-000
- Reclutamiento
- Funfarme Sjrp
-
São Paulo, Brasil, 01246 000
- Reclutamiento
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, Brasil, 01509 900
- Reclutamiento
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasil, 05651 900
- Reclutamiento
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
Vitória, Brasil, 29043 260
- Reclutamiento
- Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
-
-
-
-
-
Anderlecht, Bélgica, 1070
- Reclutamiento
- Institut Jules Bordet
-
Edegem, Bélgica, 2650
- Reclutamiento
- UZ Antwerpen
-
Ghent, Bélgica, 9000
- Terminado
- AZ Maria Middelares
-
Haine Saint Paul La Louviere, Bélgica, 7100
- Reclutamiento
- Jolimont
-
Kortrijk, Bélgica, 8500
- Reclutamiento
- Az Groeninge
-
Leuven, Bélgica, 3000
- Reclutamiento
- Universitair Ziekenhuis Leuven
-
Liège, Bélgica, 4000
- Reclutamiento
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
-
-
-
-
Daegu, Corea del Sur, 41404
- Reclutamiento
- Kyungpook National University Chilgok Hospital
-
Seoul, Corea del Sur, 05505
- Reclutamiento
- Asan Medical Center
-
Seoul, Corea del Sur, 03080
- Reclutamiento
- Seoul National University Hospital
-
Seoul, Corea del Sur, 06351
- Reclutamiento
- Samsung Medical Center
-
Seoul, Corea del Sur, 02841
- Reclutamiento
- Korea University Anam Hospital
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Severance Hospital Yonsei University Health System
-
Seoul, Corea del Sur, 06591
- Reclutamiento
- The Catholic University of Korea Seoul St Mary s Hospital
-
-
-
-
-
Badajoz, España, 06006
- Reclutamiento
- Hosp. Univ. de Badajoz
-
Barcelona, España, 08028
- Reclutamiento
- Hosp. Univ. Quiron Dexeus
-
Barcelona, España, 08003
- Reclutamiento
- Hosp. Del Mar
-
Barcelona, España, 08041
- Reclutamiento
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, España, 08035
- Reclutamiento
- Hosp Univ Vall D Hebron
-
Madrid, España, 28034
- Reclutamiento
- Hosp. Univ. Ramon Y Cajal
-
Madrid, España, 28041
- Reclutamiento
- Hosp. Univ. 12 de Octubre
-
Madrid, España, 28007
- Reclutamiento
- Hosp. Gral. Univ. Gregorio Maranon
-
Madrid, España, 28040
- Reclutamiento
- Hosp Univ Fund Jimenez Diaz
-
Madrid, España, 28002
- Reclutamiento
- Hosp San Francisco de Asis
-
Málaga, España, 29010
- Reclutamiento
- Hosp Regional Univ de Malaga
-
Pamplona, España, 31008
- Reclutamiento
- Clinica Univ. de Navarra
-
Seville, España, 41013
- Reclutamiento
- Hosp. Virgen Del Rocio
-
Valencia, España, 46010
- Reclutamiento
- Hosp. Clinico Univ. de Valencia
-
-
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85224
- Reclutamiento
- Ironwood Cancer and Research Center
-
Gilbert, Arizona, Estados Unidos, 85234
- Reclutamiento
- Banner MD Anderson Cancer Center
-
Prescott, Arizona, Estados Unidos, 86301
- Terminado
- Arizona Oncology Associates PC NAHOA
-
-
Arkansas
-
Jonesboro, Arkansas, Estados Unidos, 72401
- Reclutamiento
- St. Bernard's Medical Center
-
Springdale, Arkansas, Estados Unidos, 72762
- Reclutamiento
- Highlands Oncology Group
-
-
California
-
Bakersfield, California, Estados Unidos, 93309
- Reclutamiento
- CBCC Global Research
-
Glendale, California, Estados Unidos, 91204
- Reclutamiento
- Los Angeles Cancer Network
-
Los Alamitos, California, Estados Unidos, 90720
- Reclutamiento
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- USC Norris Comprehensive Cancer Center
-
Santa Monica, California, Estados Unidos, 90404
- Reclutamiento
- UCLA
-
Santa Rosa, California, Estados Unidos, 95403
- Reclutamiento
- Providence Medical Foundation
-
Torrance, California, Estados Unidos, 90505
- Reclutamiento
- Torrance Memorial Physicians Network
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- University of Colorado Denver Anschultz Medical Campus
-
Denver, Colorado, Estados Unidos, 80218
- Reclutamiento
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Norwich, Connecticut, Estados Unidos, 06360
- Terminado
- Eastern Connecticut Hematology & Oncology Assoc.
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33901
- Reclutamiento
- Florida Cancer Specialists South
-
Miami Beach, Florida, Estados Unidos, 33140
- Terminado
- Mount Sinai Medical Center Campus
-
Orlando, Florida, Estados Unidos, 32804
- Reclutamiento
- AdventHealth Cancer Institute
-
St. Petersburg, Florida, Estados Unidos, 33701-4553
- Reclutamiento
- Florida Cancer Specialists North Region
-
West Palm Beach, Florida, Estados Unidos, 33401-3406
- Reclutamiento
- Florida Cancer Specialists East
-
-
Georgia
-
Athens, Georgia, Estados Unidos, 30607
- Reclutamiento
- University Cancer And Blood Center LLC
-
Atlanta, Georgia, Estados Unidos, 30303
- Reclutamiento
- Grady Memorial Hospital
-
Atlanta, Georgia, Estados Unidos, 30318
- Reclutamiento
- Piedmont Cancer Institute
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Winship Cancer Institute Emory University
-
-
Illinois
-
Arlington Heights, Illinois, Estados Unidos, 60005
- Reclutamiento
- Illinois Cancer Specialists
-
Peoria, Illinois, Estados Unidos, 61615
- Reclutamiento
- Illinois CancerCare
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46237
- Reclutamiento
- Franciscan Health
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa Hospitals and Clinics
-
Waukee, Iowa, Estados Unidos, 50263
- Reclutamiento
- Mission Cancer Blood
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Reclutamiento
- Cancer Center of Kansas
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Reclutamiento
- Mary Bird Perkins Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21237
- Reclutamiento
- MedStar Franklin Square Medical Center
-
Frederick, Maryland, Estados Unidos, 21702
- Reclutamiento
- Frederick Health Hospital - James M Stockman Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- University of Michigan Rogel Cancer Center
-
Detroit, Michigan, Estados Unidos, 48202
- Reclutamiento
- Henry Ford Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Reclutamiento
- Cancer And Hematology Centers of Western Michigan PC
-
-
Mississippi
-
Hattiesburg, Mississippi, Estados Unidos, 39401
- Reclutamiento
- Hattiesburg Clinic
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School Of Medicine
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Reclutamiento
- Nebraska Cancer Specialists
-
-
New Jersey
-
East Brunswick, New Jersey, Estados Unidos, 08816
- Reclutamiento
- Astera Cancer Care
-
-
New York
-
Mineola, New York, Estados Unidos, 11501
- Reclutamiento
- Perlmutter Cancer Center at NYU Long Island
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- NYU Langone Medical Center NYU Hematology Associates
-
Shirley, New York, Estados Unidos, 11967
- Reclutamiento
- New York Cancer and Blood Specialists
-
The Bronx, New York, Estados Unidos, 10461
- Reclutamiento
- Montefiore Einstein Comprehensive Cancer Center
-
Williamsville, New York, Estados Unidos, 14221
- Reclutamiento
- University of Buffalo Kaleida Health Cancer Care
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44718
- Reclutamiento
- Gabrail Cancer Center
-
Cleveland, Ohio, Estados Unidos, 44106
- Reclutamiento
- University Hospital of Cleveland
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- Oregon Health And Science University
-
-
Pennsylvania
-
Penn Wynne, Pennsylvania, Estados Unidos, 19096
- Reclutamiento
- Alliance Cancer Specialists at Main Line
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Reclutamiento
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Reclutamiento
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232 1301
- Reclutamiento
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37404
- Reclutamiento
- Tennessee Oncology Chattanooga
-
Nashville, Tennessee, Estados Unidos, 37232
- Reclutamiento
- Vanderbilt University Medical Center
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- Tennessee Oncology
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- SCRI Oncology Partners
-
-
Texas
-
Abilene, Texas, Estados Unidos, 79606
- Reclutamiento
- Texas Oncology West Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- UT Southwestern Medical Center
-
Dallas, Texas, Estados Unidos, 75235
- Reclutamiento
- Parkland Health and Hospital System
-
Dallas, Texas, Estados Unidos, 75246
- Reclutamiento
- Texas Oncology DFW
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- MD Anderson Cancer Center
-
Round Rock, Texas, Estados Unidos, 77845
- Reclutamiento
- Baylor Scott & White Medical Center
-
San Antonio, Texas, Estados Unidos, 78240
- Reclutamiento
- Texas Oncology - San Antonio
-
Temple, Texas, Estados Unidos, 76508
- Reclutamiento
- Scott And White Memorial Hospital
-
Tyler, Texas, Estados Unidos, 75701
- Reclutamiento
- UT Health East Texas HOPE Cancer Center
-
-
Virginia
-
Arlington, Virginia, Estados Unidos, 22201
- Reclutamiento
- Virginia Cancer Specialists
-
Richmond, Virginia, Estados Unidos, 23249
- Reclutamiento
- Richmond VA Medical Center
-
Richmond, Virginia, Estados Unidos, 23298
- Reclutamiento
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Lacey, Washington, Estados Unidos, 98503
- Reclutamiento
- Providence Regional Cancer System
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Medical College Of Wisconsin
-
-
-
-
-
Avignon, Francia, 84918
- Reclutamiento
- Institut Sainte Catherine
-
Pessac, Francia, 33604
- Reclutamiento
- Hopital Haut Leveque
-
Poitiers, Francia, 86000
- Reclutamiento
- CHU De Poitiers
-
-
-
-
-
Hong Kong, Hong Kong
- Reclutamiento
- Queen Mary Hospital
-
Shatin, Hong Kong
- Reclutamiento
- Prince Of Wales Hospital
-
-
-
-
-
Eger, Hungría, 3300
- Terminado
- Markhot Ferenc Oktatokorhaz es Rendelointezet
-
Pécs, Hungría, 7624
- Terminado
- Pecsi Tudomanyegyetem
-
Szeged, Hungría, 6720
- Terminado
- Szegedi Tudomanyegyetem
-
-
-
-
-
Delhi, India, 110085
- Reclutamiento
- Rajiv Gandhi Cancer Institute and Research Centre
-
Hyderabad, India, 500032
- Reclutamiento
- Asian Institute Of Gastroenterology
-
Kolkata, India, 700053
- Reclutamiento
- B P Poddar Hospital and Medical research Limited
-
Mumbai, India, 400012
- Reclutamiento
- Tata Memorial Hospital
-
New Delhi, India, 110029
- Reclutamiento
- Safdarjung Hospital
-
Pune, India, 411004
- Reclutamiento
- Deenanath Mangeshkar Hospital and Research Centre
-
Varanasi, India, 221005
- Reclutamiento
- Mahamana Pandit Madan Mohan Malviya Cancer Centre
-
Vellore, India, 632004
- Reclutamiento
- Christian medical
-
-
-
-
-
Beer Yaakov, Israel, 70300
- Reclutamiento
- Yitzhak Shamir Medical Center
-
Haifa, Israel, 3109601
- Reclutamiento
- Rambam Medical Center
-
Jerusalem, Israel, 9112001
- Reclutamiento
- Hadassah Medical Center
-
Petah Tikva, Israel, 4941492
- Reclutamiento
- Rabin Medical Center
-
Ramat Gan, Israel, 52621
- Reclutamiento
- Sheba Medical Center
-
Tel Aviv, Israel, 6423906
- Reclutamiento
- Tel Aviv Sourasky Medical Center
-
Tel Aviv, Israel, 69710
- Reclutamiento
- Assuta MC
-
-
-
-
-
Catania, Italia, 95122
- Reclutamiento
- ARNAS Garibaldi P O Nesima
-
Florence, Italia, 50134
- Reclutamiento
- Careggi University Hospital
-
Milan, Italia, 20133
- Reclutamiento
- Istituto Dei Tumori Di Milano
-
Novara, Italia, 28100
- Reclutamiento
- Fondazione del Piemonte per I Oncologia IRCC Candiolo
-
Padova, Italia, 35128
- Reclutamiento
- Istituto Oncologico Veneto - IRCCS
-
Pisa, Italia, 56126
- Reclutamiento
- Azienda Ospedaliero Universitaria Pisana
-
Rozzano, Italia, 20089
- Reclutamiento
- Istituto Clinico Humanitas
-
Udine, Italia, 33100
- Terminado
- Azienda Sanitaria Universitaria Friuli Centrale ASU FC
-
-
-
-
-
Chiba, Japón, 260 0801
- Reclutamiento
- Chiba Cancer Center
-
Chūōku, Japón, 104 0045
- Reclutamiento
- National Cancer Center Hospital
-
Kashiwa, Japón, 277 8577
- Reclutamiento
- National Cancer Center Hospital East
-
Nagoya, Japón, 464-8681
- Reclutamiento
- Aichi Cancer Center
-
Osaka, Japón, 541 8567
- Reclutamiento
- Osaka International Cancer Institute
-
Osaka, Japón, 540 0006
- Reclutamiento
- National Hospital Organization Osaka National Hospital
-
Sakai, Japón, 590 0197
- Reclutamiento
- Kindai University Hospital
-
Shizuoka, Japón, 411 8777
- Reclutamiento
- Shizuoka Cancer Center
-
Suita, Japón, 565 0871
- Reclutamiento
- The University of Osaka Hospital
-
Tokyo, Japón, 135 8550
- Reclutamiento
- The Cancer Institute Hospital of JFCR
-
-
-
-
-
George Town, Malasia, 10450
- Reclutamiento
- Hospital Pulau Pinang
-
Ipoh, Malasia, 30450
- Reclutamiento
- Hospital Raja Permaisuri Bainun
-
Kuala Lumpur, Malasia, 59100
- Reclutamiento
- University Malaya Medical Centre
-
Kuala Lumpur, Malasia, 50586
- Reclutamiento
- Hospital Kuala Lumpur
-
Kuching, Malasia, 93586
- Reclutamiento
- Hospital Umum Sarawak
-
Putrajaya, Malasia, 62250
- Reclutamiento
- Institut Kanser Negara Clinical Research Center
-
-
-
-
-
Chihuahua City, México, 31217
- Reclutamiento
- Centro Oncologico de Chihuahua
-
Guadalajara, México, 44680
- Reclutamiento
- Actualidad Basada En La Investigacion Del Cancer
-
Mexico City, México, 14080
- Reclutamiento
- Instituto Nacional de Cancerologia
-
Mexico City, México, 06760
- Reclutamiento
- Centro Oncologico Personalizado Cope S De R L De C V
-
Monterrey, México, 64460
- Reclutamiento
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
Puebla City, México, 72530
- Reclutamiento
- Oncocenter
-
Querétaro, México, 76000
- Reclutamiento
- Cuidados Oncologicos
-
Querétaro, México, 76230
- Reclutamiento
- Health Pharma Queretaro SA de CV
-
Tijuana, México, 22010
- Reclutamiento
- COI Centro Oncologico Internacional Tijuana
-
-
-
-
-
Amersfoort, Países Bajos, 3813 TZ
- Reclutamiento
- Meander Medisch Centrum
-
Amsterdam, Países Bajos, 1066 CX
- Reclutamiento
- Antoni van Leeuwenhoek
-
Nijmegen, Países Bajos, 6525 GA
- Reclutamiento
- Radboud University Medical Center
-
Rotterdam, Países Bajos, 3015 GD
- Reclutamiento
- Erasmus MC
-
Tilburg, Países Bajos, 5042 AD
- Reclutamiento
- ETZ TweeSteden
-
-
-
-
-
Bialystok, Polonia, 15 027
- Terminado
- Bialostockie Centrum Onkologii im Marii Sklodowskiej Curie w Bialymstoku
-
Biała Podlaska, Polonia, 21 500
- Terminado
- Wojewodzki Szpital Specjalistyczny
-
Brzozów, Polonia, 36 200
- Reclutamiento
- Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
-
Gdansk, Polonia, 80 214
- Reclutamiento
- Uniwersyteckie Centrum Kliniczne
-
Gliwice, Polonia, 44 100
- Terminado
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach
-
Lodz, Polonia, 93 339
- Reclutamiento
- Instytut Centrum Zdrowia Matki Polki
-
Olsztyn, Polonia, 10 228
- Terminado
- Szpital Kliniczny MSWiA z WMCO
-
Opole, Polonia, 45 061
- Reclutamiento
- SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego
-
Warsaw, Polonia, 02 034
- Reclutamiento
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
-
-
-
-
Beijing, Porcelana, 100142
- Reclutamiento
- Beijing Cancer Hospital
-
Beijing, Porcelana, 100034
- Reclutamiento
- Peking University First Hospital
-
Beijing, Porcelana, 100050
- Reclutamiento
- Beijing Friendship Hospital Capital Medical University
-
Changchun, Porcelana, 130021
- Reclutamiento
- The First Bethune Hospital of Jilin University
-
Changsha, Porcelana, 410013
- Reclutamiento
- Hunan Cancer hospital
-
Chengdu, Porcelana, 610041
- Reclutamiento
- West China Hospital of Sichuan University
-
Ganzhou, Porcelana, 341000
- Reclutamiento
- Ganzhou Cancer Hospital
-
Guangzhou, Porcelana, 510655
- Reclutamiento
- The Sixth Affiliated Hospital Sun Yat sen University
-
Guangzhou, Porcelana, 519041
- Reclutamiento
- Guangdong Provincial People's Hospital
-
Guangzhou, Porcelana, 100142
- Reclutamiento
- Sun Yat Sen University Cancer Center
-
Hangzhou, Porcelana, 310022
- Reclutamiento
- Zhejiang Cancer Hospital
-
Hangzhou, Porcelana, 310009
- Reclutamiento
- The Second Affiliated Hospital of Zhejiang University
-
Harbin, Porcelana, 150081
- Reclutamiento
- Harbin medical university cancer hospital
-
Huizhou, Porcelana, 516001
- Reclutamiento
- Huizhou Central People's Hospital
-
Lanzhou, Porcelana, 730050
- Reclutamiento
- Gansu Provincial Cancer Hospital
-
Nanchang, Porcelana, 330006
- Reclutamiento
- The First Affiliated Hospital of NanChang University
-
Shanghai, Porcelana, 200032
- Reclutamiento
- Fudan University Shanghai Cancer Center
-
Shenyang, Porcelana, 110042
- Reclutamiento
- Liaoning Cancer Hospital and Institute
-
Tianjin, Porcelana, 300060
- Reclutamiento
- Tianjin Medical University Cancer Institute and Hospital
-
Wuhan, Porcelana, 430079
- Reclutamiento
- Hubei Cancer Hospital
-
-
-
-
-
San Juan, Puerto Rico, 00935
- Reclutamiento
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Birmingham, Reino Unido, B9 5ST
- Reclutamiento
- Birmingham Heartlands Hospital
-
Hull, Reino Unido, HU16 5JQ
- Reclutamiento
- Castle Hill Hospital
-
Leeds, Reino Unido, LS9 7TF
- Reclutamiento
- St James University Hospital
-
London, Reino Unido, EC1A 7BE
- Reclutamiento
- St Bartholomew's Hospital
-
London, Reino Unido, SW3 6JJ
- Reclutamiento
- Royal Marsden Hospital
-
London, Reino Unido, NW1 2BU
- Reclutamiento
- University College Hospital
-
Northwood, Reino Unido, HA6 2RN
- Reclutamiento
- Mount Vernon Cancer Centre
-
-
-
-
-
Brasov, Rumania, 500091
- Reclutamiento
- Centrul Medical Unirea SRL
-
Bucharest, Rumania, 013812
- Reclutamiento
- Spitalul Memorial Baneasa
-
Bucharest, Rumania, 014142
- Terminado
- Ponderas Academic Hospital
-
Bucharest, Rumania, 077190
- Terminado
- Neolife Medical Center Bucharest
-
Cluj-Napoca, Rumania, 400015
- Reclutamiento
- Institutul Oncologic 'Prof Dr. Ion Chiricuta' Cluj-Napoca
-
Craiova, Rumania, 200542
- Reclutamiento
- Clinica de Oncologie Sf Nectarie
-
Iași, Rumania, 700483
- Reclutamiento
- Institutul Regional de Oncologie Iasi
-
Oradea, Rumania, 410469
- Reclutamiento
- Pelican Impex SRL
-
-
-
-
-
Gothenburg, Suecia, 413 45
- Terminado
- Sahlgrenska Universitetssjukhuset
-
Lund, Suecia, 222 42
- Reclutamiento
- Skanes universitetssjukhus
-
Stockholm, Suecia, 171 76
- Reclutamiento
- Karolinska Universitetssjukhuset
-
Stockholm, Suecia, 118 83
- Reclutamiento
- Sodersjukhuset
-
Uppsala, Suecia, SE 751 85
- Reclutamiento
- Uppsala University
-
-
-
-
-
Bangkok, Tailandia, 10700
- Reclutamiento
- Siriraj Hospital
-
Bangkok, Tailandia, 10400
- Reclutamiento
- Ramathibodi Hospital
-
Chiang Mai, Tailandia, 50200
- Reclutamiento
- Chiang Mai University
-
Songkhla, Tailandia, 90110
- Reclutamiento
- Songklanagarind hospital
-
-
-
-
-
Kaohsiung City, Taiwán, 833
- Reclutamiento
- Chang Gung Memorial Hospital
-
Kaohsiung City, Taiwán, 80756
- Reclutamiento
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung, Taiwán, 40705
- Reclutamiento
- Taichung Veterans General Hospital
-
Tainan, Taiwán, 704
- Reclutamiento
- National Cheng Kung University Hospital
-
Taipei, Taiwán, 112
- Reclutamiento
- Taipei Veterans General Hospital
-
Taipei, Taiwán, 10043
- Reclutamiento
- National Taiwan University Hospital
-
Taoyuan, Taiwán, 333
- Reclutamiento
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Adana, Turquía (Türkiye), 01060
- Reclutamiento
- Adana City Hospital
-
Ankara, Turquía (Türkiye), 06800
- Reclutamiento
- Ankara Bilkent Sehir Hastanesi
-
Ankara, Turquía (Türkiye), 06010
- Reclutamiento
- Gulhane Egitim ve Arastirma Hastanesi
-
Ankara, Turquía (Türkiye), 06200
- Reclutamiento
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turquía (Türkiye), 06560
- Reclutamiento
- Gazi Universitesi Hastanesi
-
Antalya, Turquía (Türkiye), 07025
- Reclutamiento
- Memorial Antalya Hospital
-
Edirne, Turquía (Türkiye), 22030
- Reclutamiento
- Trakya University Medical Faculty
-
Istanbul, Turquía (Türkiye), 34147
- Reclutamiento
- Bakirkoy Training and Research Hospital
-
Istanbul, Turquía (Türkiye), 34899
- Reclutamiento
- Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi
-
Konya, Turquía (Türkiye), 42090
- Reclutamiento
- Necmettin Erbakan Universitesi Tip Fakultesi Hastanesi
-
Sakarya, Turquía (Türkiye), 54290
- Reclutamiento
- Sakarya University Training and Research Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Have histologically or cytologically confirmed adenocarcinoma of the colon or rectum. Participants must have recurrent, unresectable or metastatic disease
- Determined to have kirsten rat sarcoma viral oncogene/neuroblastoma RAS viral oncogene homolog (KRAS/NRAS), G12, G13 and v-raf murine sarcoma viral oncogene homolog B (BRAF) V600X (X represents any single amino acid change from the original amino acid) wild type status by local and/or central next-generation sequencing (NGS) testing
- Must agree to the submission of fresh or archival tumor tissue post progression from the most recent therapy, if clinically feasible
- Have measurable disease according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1
- Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1
- Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy. Participants can receive anti-VEGF as prior line of therapy
Exclusion Criteria:
- Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
- Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: amivantamab, cetuximab or bevacizumab or any component of FOLFIRI
- Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
- Participant with known human epidermal growth factor receptor 2 (HER2)- positive/amplified tumor
- Has prior exposure to irinotecan, any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A: Amivantamab + FOLFIRI
Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium [folinic acid] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. |
Amivantamab will be administered.
Otros nombres:
5-fluorouracil will be administered as chemotherapy regimen. Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Otros nombres:
Irinotecan will be administered as chemotherapy regimen. |
|
Comparador activo: Arm B: Cetuximab or Bevacizumab + FOLFIRI
Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met. |
5-fluorouracil will be administered as chemotherapy regimen. Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Otros nombres:
Cetuximab will be administered.
Otros nombres:
Irinotecan will be administered as chemotherapy regimen. Bevacizumab will be administered.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Periodo de tiempo: Up to 2 years 1 month
|
PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by BICR using response evaluation criteria in solid tumors (RECIST) version (v)1.1. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable RECIST v1.1 assessment date. |
Up to 2 years 1 month
|
|
Overall Survival (OS)
Periodo de tiempo: Up to 4 years 4 months
|
OS is defined as the time from the date of randomization to the date of participant's death due to any cause. |
Up to 4 years 4 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR) as Assessed by BICR
Periodo de tiempo: Up to 4 years 4 months
|
ORR is defined as the percentage of randomized participants achieving partial response (PR) or complete response (CR), as determined by BICR using RECIST v1.1 criteria. |
Up to 4 years 4 months
|
|
ORR as Assessed by Investigator
Periodo de tiempo: Up to 4 years 4 months
|
ORR is defined as the percentage of randomized participants achieving partial response (PR) or complete response (CR), as determined by investigator using RECIST v1.1 criteria. |
Up to 4 years 4 months
|
|
Progression Free Survival as Assessed by Investigator
Periodo de tiempo: Up to 4 years 4 months
|
PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by investigator. |
Up to 4 years 4 months
|
|
Duration of Response (DoR) as Assessed by BICR
Periodo de tiempo: Up to 4 years 4 months
|
DoR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as assessed by BICR. |
Up to 4 years 4 months
|
|
Duration of Response as Assessed by Investigator
Periodo de tiempo: Up to 4 years 4 months
|
DoR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as assessed by investigator. |
Up to 4 years 4 months
|
|
Time to Response (TTR) as Assessed by BICR
Periodo de tiempo: Up to 4 years 4 months
|
TTR is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression or subsequent systemic anti-cancer therapy or curative-intent procedure, for participants who have PR or CR as BOR, as assessed by BICR. |
Up to 4 years 4 months
|
|
TTR as Assessed by Investigator
Periodo de tiempo: Up to 4 years 4 months
|
TTR is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression or subsequent systemic anti-cancer therapy or curative-intent procedure, for participants who have PR or CR as BOR, as assessed by investigator. |
Up to 4 years 4 months
|
|
Progression Free Survival After Subsequent Therapy (PFS2)
Periodo de tiempo: Up to 4 years 4 months
|
PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent systemic anticancer therapy, based on investigator assessment or death, whichever comes first. |
Up to 4 years 4 months
|
|
Disease Control Rate (DCR) as Assessed by BICR
Periodo de tiempo: Up to 4 years 4 months
|
DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with a minimum duration of 7 weeks) as defined by BICR using RECIST v1.1. |
Up to 4 years 4 months
|
|
Disease Control Rate as Assessed by Investigator
Periodo de tiempo: Up to 4 years 4 months
|
DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with a minimum duration of 7 weeks) as assessed by investigator. |
Up to 4 years 4 months
|
|
Time to Treatment Failure
Periodo de tiempo: Up to 4 years 4 months
|
Time to treatment failure is defined as time from randomization to discontinuation of therapy for any reason including death, progression, toxicity, or initiation of new anticancer therapy. |
Up to 4 years 4 months
|
|
Curative Resection (R0) Rate
Periodo de tiempo: Up to 4 years 4 months
|
Curative resection (R0) rate is defined as the percentage of randomized participants who underwent curative-intent surgery where the residual tumor classification was R0. |
Up to 4 years 4 months
|
|
Number of Participants with Adverse Events (AEs) by Severity
Periodo de tiempo: Up to 4 years 4 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to 4 years 4 months
|
|
Number of Participants with Abnormalities in Laboratory Values
Periodo de tiempo: Up to 4 years 4 months
|
Participants with abnormalities in laboratory values (such as serum chemistry, hematology) will be reported. |
Up to 4 years 4 months
|
|
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score
Periodo de tiempo: From baseline up to 4 years 4 months
|
The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms. |
From baseline up to 4 years 4 months
|
|
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-C30
Periodo de tiempo: Up to 4 years 4 months
|
Time to worsening in symptoms and functioning as measured by EORTC QLQ-C30 score will be reported. The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms. |
Up to 4 years 4 months
|
|
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29) Score
Periodo de tiempo: From baseline up to 4 years 4 months
|
The EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ-CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms. |
From baseline up to 4 years 4 months
|
|
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-CR29 Score
Periodo de tiempo: Up to 4 years 4 months
|
Time to worsening in symptoms and functioning as measured by EORTC QLQ-CR29 will be reported. EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ-CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms. Change from baseline in the EORTC QLQ-CR29 score will be reported. |
Up to 4 years 4 months
|
|
Overall Side Effect Burden as Measured by European Organisation for Research and Treatment of Cancer (EORTC) Item 168 Scale Score
Periodo de tiempo: Up to 4 years 4 months
|
EORTC item 168 is a single item used to measure the overall impact of treatment side effects. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much. Higher scores indicates severe symptoms. |
Up to 4 years 4 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades intestinales
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades del Colon
- Neoplasias colorrectales
- Aminoácidos, péptidos y proteínas
- Proteínas
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Campeptecina
- Alcaloides
- Enzimas y coenzimas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Pirimidinas
- Formiltetrahidrofolatos
- Tetrahidrofolatos
- Ácido fólico
- Pterins
- Pteridinas
- Uracílico
- Pirimidinonas
- Coenzimas
- Bevacizumab
- Irinotecán
- Cetuximab
- Fluorouracilo
- Leucovorina
- Levoleucovorina
- amivantamab
Otros números de identificación del estudio
- 61186372COR3002
- 2024-513853-66-00 (Identificador de registro: EUCT number)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .